Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 521

1.

Genes and functions from breast cancer signatures.

Huang S, Murphy L, Xu W.

BMC Cancer. 2018 Apr 27;18(1):473. doi: 10.1186/s12885-018-4388-4.

2.

Identifying statistically significant combinatorial markers for survival analysis.

Relator RT, Terada A, Sese J.

BMC Med Genomics. 2018 Apr 20;11(Suppl 2):31. doi: 10.1186/s12920-018-0346-x.

3.

Single drug biomarker prediction for ER- breast cancer outcome from chemotherapy.

Chen YZ, Kim Y, Soliman HH, Ying G, Lee JK.

Endocr Relat Cancer. 2018 Jun;25(6):595-605. doi: 10.1530/ERC-17-0495. Epub 2018 Mar 29.

4.

UBASH3B promotes tamoxifen resistance and could be negatively regulated by ESR1.

Jin K, Lan H, Zhang J, Lv J, Chen Y, Yu K, Wang W.

Oncotarget. 2017 Dec 22;9(9):8326-8333. doi: 10.18632/oncotarget.23608. eCollection 2018 Feb 2.

5.

Applying Expression Profile Similarity for Discovery of Patient-Specific Functional Mutations.

Meng G.

High Throughput. 2018 Feb 22;7(1). pii: E6. doi: 10.3390/ht7010006.

6.

Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.

Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E.

Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):1913-1918. doi: 10.1073/pnas.1719760115. Epub 2018 Feb 6.

PMID:
29434041
7.

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.

Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F.

Cancer Manag Res. 2018 Jan 15;10:91-103. doi: 10.2147/CMAR.S146658. eCollection 2018. Review.

8.

Immune gene expression and response to chemotherapy in advanced breast cancer.

Foukakis T, Lövrot J, Matikas A, Zerdes I, Lorent J, Tobin N, Suzuki C, Brage SE, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Fernö M, Skoog L, Bergh J, Hatschek T.

Br J Cancer. 2018 Feb 20;118(4):480-488. doi: 10.1038/bjc.2017.446. Epub 2018 Jan 25.

PMID:
29370583
9.

MultiDCoX: Multi-factor analysis of differential co-expression.

Liany H, Rajapakse JC, Karuturi RKM.

BMC Bioinformatics. 2017 Dec 28;18(Suppl 16):576. doi: 10.1186/s12859-017-1963-7.

10.

Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome.

Benito A, Polat IH, Noé V, Ciudad CJ, Marin S, Cascante M.

Oncotarget. 2017 Oct 7;8(63):106693-106706. doi: 10.18632/oncotarget.21601. eCollection 2017 Dec 5.

11.

The GDNF Family: A Role in Cancer?

Fielder GC, Yang TW, Razdan M, Li Y, Lu J, Perry JK, Lobie PE, Liu DX.

Neoplasia. 2018 Jan;20(1):99-117. doi: 10.1016/j.neo.2017.10.010. Epub 2017 Dec 12. Review.

12.

Network Modularity in Breast Cancer Molecular Subtypes.

Alcalá-Corona SA, de Anda-Jáuregui G, Espinal-Enríquez J, Hernández-Lemus E.

Front Physiol. 2017 Nov 17;8:915. doi: 10.3389/fphys.2017.00915. eCollection 2017.

13.

A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.

Zhao Y, Varn FS, Cai G, Xiao F, Amos CI, Cheng C.

Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):86-95. doi: 10.1158/1055-9965.EPI-17-0478. Epub 2017 Nov 15.

PMID:
29141854
14.

An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.

Palazon A, Tyrakis PA, Macias D, Veliça P, Rundqvist H, Fitzpatrick S, Vojnovic N, Phan AT, Loman N, Hedenfalk I, Hatschek T, Lövrot J, Foukakis T, Goldrath AW, Bergh J, Johnson RS.

Cancer Cell. 2017 Nov 13;32(5):669-683.e5. doi: 10.1016/j.ccell.2017.10.003.

15.

Augmented expression of polo-like kinase 1 indicates poor clinical outcome for breast patients: a systematic review and meta-analysis.

Zhang Y, Wu Z, Liu D, Wang M, Xiao G, Wang P, Sun X, Ren H, Tang SC, Du N.

Oncotarget. 2017 Apr 20;8(34):57723-57732. doi: 10.18632/oncotarget.17301. eCollection 2017 Aug 22. Review.

16.

Molecular genetics complexity impeding research progress in breast and ovarian cancers.

Gupta I, Burney I, Al-Moundhri MS, Tamimi Y.

Mol Clin Oncol. 2017 Jul;7(1):3-14. doi: 10.3892/mco.2017.1275. Epub 2017 May 29.

17.

A Novel Unsupervised Algorithm for Biological Process-based Analysis on Cancer.

Song T, Cao S, Tao S, Liang S, Du W, Liang Y.

Sci Rep. 2017 Jul 5;7(1):4671. doi: 10.1038/s41598-017-04961-6.

18.

Mechanical cue-induced YAP instructs Skp2-dependent cell cycle exit and oncogenic signaling.

Jang W, Kim T, Koo JS, Kim SK, Lim DS.

EMBO J. 2017 Sep 1;36(17):2510-2528. doi: 10.15252/embj.201696089. Epub 2017 Jul 3.

PMID:
28673931
19.

Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis.

Delou JMA, Vignal GM, Índio-do-Brasil V, Accioly MTS, da Silva TSL, Piranda DN, Sobral-Leite M, de Carvalho MA, Capella MAM, Vianna-Jorge R.

Breast Cancer (Dove Med Press). 2017 Jun 10;9:415-428. doi: 10.2147/BCTT.S131284. eCollection 2017.

20.

Glycosylation of KEAP1 links nutrient sensing to redox stress signaling.

Chen PH, Smith TJ, Wu J, Siesser PF, Bisnett BJ, Khan F, Hogue M, Soderblom E, Tang F, Marks JR, Major MB, Swarts BM, Boyce M, Chi JT.

EMBO J. 2017 Aug 1;36(15):2233-2250. doi: 10.15252/embj.201696113. Epub 2017 Jun 29.

PMID:
28663241

Supplemental Content

Support Center